CMS Expands Access to Lifesaving Gene Therapies Through Innovative State AgreementsParticipating states to test outcomes-based payments for sickle cell disease treatments, improving care while lowering long-term costsThe Centers for Medicare & Medicaid Services (CMS) announced today that 33 states, plus the District of Columbia and Puerto Rico, will participate in the Cell and Gene Therapy (CGT) Access Model, a bold new approach to delivering cutting-edge treatments for people on Medicaid living with sickle cell disease. Participating states represent approximately 84% of Medicaid benefici...
HALO NEWSLETTER
Join HALO today and unlock this story instantly — It's Free